Announcement • Mar 27
Numinus Wellness Provides Update Regarding Listing Status Numinus Wellness Inc. is providing an update regarding its listing status on the Toronto Stock Exchange ("TSX"). As previously disclosed in the Company's management information circular dated July 29, 2025, and as approved by shareholders at the Company's annual general meeting held on August 28, 2025 (with voting results subsequently disclosed on September 3, 2025), shareholders authorized the Board of Directors, in its discretion, to voluntarily delist the Company's common shares from the TSX if deemed to be in the best interests of the Company. Further to Numinus' news release of March 13, 2026, on March 19, 2026 the Continued Listing Committee of the TSX met and determined to delist the Company's common shares from the TSX, effective April 22, 2026. While this delisting does not result from a request from the Company, it is consistent with the authorization of the shareholders to delist Numinus from the TSX, and aligns with the Company's previously disclosed strategic considerations. As the Company remains subject to a cease trade order (the "CTO"), the delisting from the TSX will not change the current trading status of its securities, which are not presently tradable in Canada. The Company will continue to be a reporting issuer in all applicable Canadian jurisdictions. Looking ahead for Numinus, management is pleased to advise that an application has been filed to list the Company's shares on the Canadian Securities Exchange (the "CSE"). If approved, a listing on the CSE could only take effect after the CTO has been revoked. The listing of the Company's common shares on the CSE is subject to the Company meeting the CSE's listing requirements, which cannot be guaranteed. Management remains focused on: completing the work to have the audit completed for the Company's financial statements for the year ended August 31, 2026; satisfying all regulatory requirements necessary to have the CTO revoked; and advancing an application to list its common shares on the CSE. Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. Announcement • Jul 14
Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025 Numinus Wellness Inc., Annual General Meeting, Aug 28, 2025. New Risk • Jan 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended May 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$15m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported May 2024 fiscal period end). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (CA$16.1m market cap, or US$11.2m). Announcement • Dec 18
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI). Stella MSO, Inc. signed a definitive agreement to acquire Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) for $3.5 million on November 15, 2024. A cash consideration of $2.08 million will be paid by Stella MSO, Inc. Stella MSO, Inc. will pay a deferred payment of $0.75 million cash paid over six equal monthly instalments in 2025 and of $0.7 million cash to be paid in 2025. The transaction is expected to close on or before November 30, 2024.
Stella MSO, Inc. completed the acquisition of Five Wellness Clinics from Numinus Wellness Inc. (TSX:NUMI) on December 17, 2024. Breakeven Date Change • Jul 15
No longer forecast to breakeven The analyst covering Numinus Wellness no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of CA$4.03m in 2026. New forecast suggests the company will make a loss of CA$2.53m in 2026. Reported Earnings • Jul 14
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: CA$0.019 loss per share (improved from CA$0.028 loss in 3Q 2023). Revenue: CA$4.35m (down 28% from 3Q 2023). Net loss: CA$5.12m (loss narrowed 30% from 3Q 2023). Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Jul 11
Numinus Wellness Inc. to Report Q3, 2024 Results on Jul 11, 2024 Numinus Wellness Inc. announced that they will report Q3, 2024 results After-Market on Jul 11, 2024 New Risk • Jun 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$17m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (CA$14.4m market cap, or US$10.5m). Announcement • Jun 08
Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD Numinus Wellness Inc. comments on the results of June 4, 2024 meeting of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory Committee ("PDAC"). The independent committee reviewed Lykos Therapeutics' new drug application for MDMA (midomafetamine capsules) used in combination withpsychological intervention for individuals with post-traumatic stress disorder ("PTSD"). The PDAC voted against recommending approval of MDMA for PTSD in a majority decision where 2 of 11 found that the available data demonstrates MDMA's effectiveness in PTSD patients, and one committee member found that the benefits of MDMA outweigh its risks for treating PTSD patients based on available data. The FDA is expected to decide on Lykos' new drug application in August this year and is not bound by the PDAC's guidance. Advisory committees, like PDAC, make non-binding recommendations to the FDA. Historically, between 2010 and 2021, the FDA approved subject treatments in 97% of cases where the committee recommended approval and in 33% of cases where the committee recommended against approval. 1 There can be no assurance as to the FDA's decision with respect to Lykos' MDMA new drug application. Pending the approval of new medications for the treatment of mental health conditions, Spravato® (esketamine), and ketamine continue to be available to practitioners. The Numinus US clinic network has delivered over 43,600 such treatments to patients. Through the auspices of Health Canada's Special Access Program, Numinus clinics have also treated several patients with MDMA and psilocybin in Canada. Through Cedar Clinical Research, Numinus has conducted clinical research involving four psychedelic medicines administered through different modalities involving 50 subjects over the past 2.5 years. At the same time, company's comprehensive practitioner training program prepares the Numinus team and trainees to treat patients across multiple medications and modalities, including ketamine and MDMA. Announcement • May 30
Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy Numinus Wellness Inc. announced that Health Canada has approved the Company's Clinical Trial Application to examine the feasibility of a group model in MDMA-assisted psychotherapy enrolling trainee practitioners as participants. The study aims to enhance comprehension of the ideal number of therapists needed to administer MDMA-assisted psychotherapy group sessions effectively. Additionally, the trial offers eligible trainees the chance to develop core competencies through observing seasoned therapists conduct MDMA-assisted psychotherapy sessions and legally experience MDMA themselves in a therapeutic setting as healthy research subjects. The clinical trial is formally titled "Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. Reported Earnings • Apr 14
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: CA$0.023 loss per share (improved from CA$0.028 loss in 2Q 2023). Revenue: CA$5.03m (down 6.0% from 2Q 2023). Net loss: CA$5.95m (loss narrowed 19% from 2Q 2023). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Announcement • Apr 10
Numinus Wellness Inc. to Report Q2, 2024 Results on Apr 15, 2024 Numinus Wellness Inc. announced that they will report Q2, 2024 results After-Market on Apr 15, 2024 Announcement • Mar 20
Numinus Wellness Inc. Submits Clinical Trial Application Numinus Wellness Inc. announced that it has submitted a Clinical Trial Application to Health Canada to examine the feasibility of a group model in MDMA-assisted psychotherapy enrollee practitioners as participants. If approved, the trial would allow Numinus to study MDMA-assisted psychotherapy with groups and better understand the optimum number of therapists required to deliver the programs safely. It may also provide eligible trainees with the opportunity to build core competencies and legally experience MDMA. The clinical trial is formally titled Phase 1 Exploration of Feasibility and Optimal Therapist Numbers in Group Model MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and Practitioner Training. If approved, it will be the first of its kind. Announcement • Mar 09
Numinus Wellness Inc., Annual General Meeting, May 21, 2024 Numinus Wellness Inc., Annual General Meeting, May 21, 2024. Announcement • Feb 16
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 6 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 50,000,000
Price\Range: CAD 0.12 Reported Earnings • Jan 16
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint First quarter 2024 results: CA$0.02 loss per share (improved from CA$0.024 loss in 1Q 2023). Revenue: CA$5.95m (up 4.9% from 1Q 2023). Net loss: CA$4.41m (loss narrowed 30% from 1Q 2023). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. Announcement • Dec 19
Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024 Numinus Wellness Inc., Annual General Meeting, Feb 26, 2024. Board Change • Dec 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Member of the Clinical Advisory Council Pam Kryskow was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Dec 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: CA$0.12 loss per share (improved from CA$0.17 loss in FY 2022). Revenue: CA$23.2m (up 257% from FY 2022). Net loss: CA$30.3m (loss narrowed 33% from FY 2022). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 10.0%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Announcement • Nov 22
Numinus Wellness Inc. to Report Q4, 2023 Results on Nov 29, 2023 Numinus Wellness Inc. announced that they will report Q4, 2023 results After-Market on Nov 29, 2023 Announcement • Oct 05
Numinus Wellness Inc. Introduces Its Innovative and Comprehensive Psychedelic Program for Individuals Surging from Mental Distress Associated with Chronic and Serious Illness Through Cedar Clinical Research Numinus Wellness Inc. introduced its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical Research facilities, the program encompasses four key initiatives that showcase Numinus' commitment to advancing psychedelic research and its potential for healing. Group Psilocybin Pilot Study Numinus Chief Science Officer, Dr. Paul Thielking, is the senior author of a recently published study of the safety, feasibility, and possible efficacy of group-administered psilocybin for depressed cancer patients. This study not only demonstrates the possible therapeutic benefits of psilocybin but also highlights the immense potential the group model holds for reducing the costs associated with psychedelic therapy. Numinus has also completed a group ketamine-assisted therapy intervention pilot for subjects suffering from chronic and serious illnesses. This pilot project showcased the effectiveness of ketamine-assisted therapy in alleviating depression and psychological distress associated with these conditions. This endeavor underscores Numinus' commitment to exploring innovative psychedelic-assisted therapy models for patients in need of new treatment options. Group Psilocybin Project Building on the success of the ketamine pilot project and the group psilocybin study, Numinus is thrilled to announce an upcoming follow-up group psilocybin project. Approved by both the U.S. Food and Drug Administration (FDA) and an Institutional Review Board (IRB), this study will, among other things, reduce the therapist to patient ratio while continuing to evaluate the impact of psilocybin-assisted therapy on cancer patients with depression. Subject to the availability of legal psilocybin- assisted therapy under applicable law, the results of this research may contribute to reducing costs and enhancing access for this patient population in the future. Breakeven Date Change • Sep 01
Forecast to breakeven in 2026 The analyst covering Numinus Wellness expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$8.81m in 2026. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Reported Earnings • Jul 18
Third quarter 2023 earnings: EPS misses analyst expectations Third quarter 2023 results: CA$0.028 loss per share. Revenue: CA$6.03m (up CA$5.29m from 3Q 2022). Net loss: CA$7.29m (loss widened 4.0% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 50%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Jun 30
Numinus Wellness Inc. to Report Q3, 2023 Results on Jul 17, 2023 Numinus Wellness Inc. announced that they will report Q3, 2023 results After-Market on Jul 17, 2023 Announcement • Jun 15
Numinus Wellness Inc. Appoints Nikhil Handa as Chief Financial Officer, Effective from June 15, 2023 Numinus Wellness Inc. announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executive search. Current Chief Financial Officer, John Fong, will be stepping down effective end of day to focus on family health matters. Mr. Fong will remain involved with the Company during the incoming CFO transition period to ensure a seamless transfer of responsibilities. Most recently, Mr. Handa was CFO at The Supreme Cannabis Company Inc., where he led finance, investor relations and corporate development. At Supreme, Mr. Handa led the restructuring of the company to focus on profitable growth, and was responsible for executing the sale of Supreme to Canopy Growth Corporation. Prior to this, he led finance at Well.ca, a leading digital health and wellness company. In that role he led the finance function, provided leadership across various aspects of operations and drove key strategic initiatives including the sale of Well.ca to McKesson Canada. Over the course of his career, Mr. Handa also held a variety of senior finance and operational roles at Restaurant Brands International. Mr. Handa was part of the mergers and acquisition group of RBC Capital Markets, where he helped advise the management teams and board of directors of private and public companies on various types of transactions across Canada, the U.S., and globally. Announcement • Jun 06
Numinus Wellness Inc. Announces Cedar Clinical Research Numinus Wellness Inc. announced Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder. CCR's research clinic in Draper, Utah, is the top enrolling site for the research study - having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic - in Murray, Utah. The MindMed study aims to enroll up to 200 participants who will receive a single administration of 25 ug, 50 ug, 100 ug or 200 ug of MM-120 or placebo. Topline results are expected to be announced by MindMed in late 2023. Announcement • May 31
Numinus Wellness Inc. Announces to Research COMP360 Psilocybin Therapy in Treatment-Resistant Depression as Part of Large Phase 3 Study Numinus Wellness Inc. announced that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy. Dr. Paul Thielking, Chief Science Officer at Numinus, and the team have begun accepting people with TRD who fulfill certain eligibility criteria to join the study. The study in Draper, Utah, is a part of COMPASS Pathway's phase 3 program in TRD. The international program is composed of two pivotal trials, each with a long-term follow-up component. It will enroll over 800 participants, with top line data expected in summer 2024 and mid-2025. The launch of the phase 3 program follows positive results from COMPASS Pathways' phase 2b trial, published in the New England Journal of Medicine, the world's leading peer-reviewed medical journal. The objective of the randomized, controlled, double-blind phase 2b study was to understand the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. After a single 25mg dose of COMP360 psilocybin, in combination with psychological support, 29.1% of participants with TRD were in remission by week 3. Announcement • May 26
Numinus Wellness Inc Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy Numinus Wellness Inc. announced several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024. In anticipation of this regulatory approval, Numinus has undertaken several initiatives to prepare the company for a rapid rollout of MDMA-AT services (using the MAPS protocol), including the recently launched Numinus NetworkTM clinic expansion program, reallocation of resources towards revenue producing activities, cost containment initiatives, and preparation for insurance reimbursement systems. Reported Earnings • Apr 14
Second quarter 2023 earnings released: CA$0.028 loss per share (vs CA$0.038 loss in 2Q 2022) Second quarter 2023 results: CA$0.028 loss per share (improved from CA$0.038 loss in 2Q 2022). Revenue: CA$5.35m (up CA$4.57m from 2Q 2022). Net loss: CA$7.33m (loss narrowed 6.5% from 2Q 2022). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Feb 02
Numinus Wellness Inc. Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training Using Psilocybe Cubensis Tea Numinus Wellness Inc. announced that it has received approval from Health Canada for its experiential training study that will test the safety and clinical efficacy of whole Psilocybe cubensis tea for therapeutic use, and enable practitioners to further their understanding of psychedelic-assisted therapy through experiential training. The clinical trial, formally titled A Phase 1, Open-Label, Single-Arm Study to Evaluate Psilocybin Experiential Training in Healthy Volunteers and Expand Knowledge and Qualifications of Therapists Planning to Conduct Psilocybin-Assisted Therapy (NUMT2), will initially be conducted at Numinus' clinic in Vancouver, and will begin selecting volunteers in the next several weeks. Study subjects will be selected from practitioners who have trained or are currently training to provide psilocybin-assisted therapy through Numinus' Practitioner Training Program or other approved training programs. Initial results from the study are expected to be published in the second half of 2023. The protocol for the clinical trial will include three sessions per study participant: one preparatory session, one dosing session, and one integration session, which will be followed by an observation period and participant interviews and questionnaires. Over the course of the clinical trial, each experiential training study volunteer will participate both as a study participant receiving the protocol and as an observer for another participant's sessions. The clinical trial will use Numinus Bioscience's EnfiniTea, a whole mushroom Psilocybe tea product delivering 25mg of psilocybin to patients when administered as directed, for trial dosing. EnfiniTea is produced using Numinus' own validated strain of Psilocybe cubensis BP-Star, and is uniquely shelf stable, consistently dosed and economical to produce. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with demonstrable need. Reported Earnings • Jan 17
First quarter 2023 earnings released: CA$0.024 loss per share (vs CA$0.026 loss in 1Q 2022) First quarter 2023 results: CA$0.024 loss per share. Revenue: CA$5.67m (up CA$4.88m from 1Q 2022). Net loss: CA$6.30m (loss widened 18% from 1Q 2022). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Jan 05
Numinus Wellness Inc. to Report Q1, 2023 Results on Jan 16, 2023 Numinus Wellness Inc. announced that they will report Q1, 2023 results After-Market on Jan 16, 2023 Announcement • Dec 20
Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023 Numinus Wellness Inc., Annual General Meeting, Feb 15, 2023. Announcement • Dec 10
Numinus Wellness Inc. Submits Clinical Trial Application to Health Canada for Experiential Psilocybin Assisted Therapy Training Research Numinus Wellness Inc. announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy the ability to experience and observe psilocybin sessions to further their understanding and PAT education. Additionally, the clinical trial will use Numinus Bioscience's EnfiniTea, a whole mushroom Psilocybe tea product, fortrial dosing. This is one of the first clinical trials globally that will be conducted with whole Psilocybe mushrooms, to assess their safety. Reported Earnings • Dec 02
Full year 2022 earnings released: CA$0.21 loss per share (vs CA$0.11 loss in FY 2021) Full year 2022 results: CA$0.21 loss per share (further deteriorated from CA$0.11 loss in FY 2021). Revenue: CA$6.49m (up 329% from FY 2021). Net loss: CA$44.9m (loss widened 139% from FY 2021). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Pharmaceuticals industry in Canada. Announcement • Nov 30
Numinus Wellness Inc. Reports Impairment of Good Will for the Fourth Quarter Ended August 31, 2022 Numinus Wellness Inc. reported impairment charges for the fourth quarter ended August 31, 2022. For the quarter, the company reported impairment of goodwill $13,275,005 against $1,581,210 a year ago. Board Change • Nov 16
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Independent Director Allen Morishita is the most experienced director on the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Oct 29
Numinus Wellness Inc. Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness Numinus Wellness Inc. announced the launch of its Ketamine for Chronic and Serious Medical Illness Program. This new program will be introduced first in Numinus' clinics in Utah, British Columbia and Quebec. The Company intends to expand the program to other clinics in later months. "Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain. In the US alone, six million people could benefit from palliative care, but current treatments have gaps that leave patients struggling to cope with distress," said Dr. Neil Barclay (MD), VP, Product and Protocol Development, Numinus. "Numinus' program addresses this gap by providing safe, evidence-based ketamine- assisted therapy that is specifically designed for this patient population and serves as an adjunct to patients' existing treatment." Numinus' program will offer ketamine-assisted therapy alongside additional community support, and has a targeted focus on improving patients' physical, emotional, mental and spiritual suffering caused by their illness. Care will be provided by health care professionals who are specifically trained in chronic and serious medical illness. They will work with each patient's existing health care team to ensure they receive an integrated experience. Announcement • Oct 06
Numinus Develops Mushroom Tea for Use in Psychedelic Research Numinus Wellness Inc. announced that its research division, Numinus Bioscience, has developed a psilocybin-containing tea bag for use in clinical research and, if appropriate regulatory approvals are granted, eventual treatment of clients in psychedelic-assisted therapy. The research behind the tea bag involved the development of processes and procedures to deliver 25mg per dose and the use of Numinus' validated strains of Psilocybe cubensis. The tea bag will be studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus' research, including trial partnerships at Cedar Clinical Research, Numinus' clinical trial management division. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which health care providers can apply to provide psilocybin-assisted therapy, among other psychedelic-assisted therapies, to patients with demonstrable need. Announcement • Sep 20
Numinus Now Offers Ketamine-Assisted Therapy in Toronto Numinus Wellness Inc. announced that its Toronto clinic, the Neurology Centre of Toronto (NCT) by Numinus, is now offering ketamine-assisted therapy for patients with neurologic conditions. The new service will be led by a psychologist and follow Numinus' existing protocol for ketamine- assisted therapy, already in use in its other locations in Canada and the US, which includes sessions for medical screening, medicine dosing and therapy for integration. The protocol will be modified to ensure it is appropriate for patients with neurologic conditions. A group of existing patients have been reviewed as candidates, with plans to provide treatment to more patients following evaluation of the initial cohort. In addition to ketamine-assisted therapy, NCT is expanding its capabilities to support applications for other psychedelic-assisted therapies through Health Canada's Special Access Program (SAP). The SAP is a federal program through which patients with demonstrable need can apply for access to investigational medical treatments that are not yet available to the public, including therapies using psychedelics such as MDMA and psilocybin. Announcement • Sep 14
Numinus Wellness Inc. to Report Q4, 2022 Results on Nov 29, 2022 Numinus Wellness Inc. announced that they will report Q4, 2022 results on Nov 29, 2022 Reported Earnings • Jul 15
Third quarter 2022 earnings released: CA$0.033 loss per share (vs CA$0.025 loss in 3Q 2021) Third quarter 2022 results: CA$0.033 loss per share (down from CA$0.025 loss in 3Q 2021). Net loss: CA$7.01m (loss widened 45% from 3Q 2021). Over the next year, revenue is forecast to grow 550%, compared to a 97% growth forecast for the industry in Canada. Announcement • Jul 07
Numinus Wellness Inc. to Report Q3, 2022 Results on Jul 14, 2022 Numinus Wellness Inc. announced that they will report Q3, 2022 results After-Market on Jul 14, 2022 Announcement • Jun 24
Numinus Wellness Inc. Announces Launch of Pilots Mental Health Program for Corporate Clients in Utah Numinus Wellness Inc. (‘Numinus’, the ‘Company’) announced the launch of a Utah-based pilot program to help businesses improve employee mental health by offering ketamine-assisted psychotherapy (KAP) as a health benefit for eligible employees (‘Corporate KAP’). While Numinus' Utah clinics, operating under the Cedar Psychiatry brand, have secured insurance coverage from select insurance companies for direct billing of ketamine for treatment-resistant depression, access remains a challenge for many patients. To bridge this gap, Cedar Psychiatry and Utah-based HempLucid have been piloting Corporate KAP since 2019 to ensure that its employees with a mental health diagnosis can access the care they need. Per the arrangement, HempLucid covers the cost of ketamine infusions while leveraging its existing healthcare insurance plan to support the therapy component of KAP. With mental illness considered among the higher cost-drivers for employers, investing in workers' mental health is becoming a top priority for business leaders. Mental illness accounts for 70% of workplace disability costs. A study by Deloitte found that the median yearly return-on-investment of CAD 1.00 spent on mental health programs was CAD 2.18 among companies that had mental health initiatives in place for three or more years. Corporate KAP is an innovative way to help employers increase productivity, lower absenteeism and reduce disability costs by improving employee mental health. Announcement • Jun 23
Numinus Wellness Inc. Announces That Its Subsidiary Numinus Bioscience Inc Applies for International Patent Filing of Psychedelics Production Process Numinus Wellness Inc. announced that its subsidiary Numinus Bioscience Inc. has filed a patent application to the World Intellectual Property Organization (WIPO), an agency of the United Nations, for a rapid production process for Psilocybe and other fungi species containing psilocybin and other compounds. A provisional patent application for the process was submitted to the United States Patent & Trademark Office (USPTO) on June 24, 2021. With this additional filing, international patent protection would extend to all WIPO member states that have signed the Patent Cooperation Treaty (PCT), including Australia, Germany, Netherlands and the United Kingdom, where psychedelic research is currently active. The purpose of the process is to significantly increase production of therapeutics for use in psychedelic-assisted therapy, while reducing product variability, increasing production efficiency and ultimately reducing commercialization costs. Since the initial filing, data-sets validating the process for additional fungi specifies have been completed, broadening its potential application and scope from psilocybin to other active compounds. Announcement • Jun 11
Numinus Wellness Inc. Announces Executive Changes Numinus Wellness Inc. announced the acquisition of Novamind Inc. has completed, following Novamind's receipt of a final order from the BC Supreme Court. Numinus announced the appointments of Dr. Reid Robison (MD) as Chief Clinical Officer and Dr. Paul Thielking (MD) as Chief Science Officer, who both join the Company from Novamind. Dr. Robison was most recently Chief Medical Officer at Novamind. He is a board-certified psychiatrist and co-founder of Cedar Psychiatry and serves as the Medical Director for the Center for Change, a leading center for the treatment of eating disorders. He was previously a coordinating investigator for a study on MDMA-assisted therapy for eating disorders, sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS). As an early adopter and researcher of the use of ketamine in psychiatry, Dr. Robison also led a pivotal intravenous ketamine study for treatment-resistant depression by Janssen, leading up to that company's recent FDA-approval of Spravato™. To date, Dr. Robison has guided thousands of ketamine-assisted therapy sessions and hundreds of Spravato™ dosing sessions. Dr. Robison is an adjunct professor at both the University of Utah and Brigham Young University. Dr. Thielking was most recently Chief Scientific Officer at Novamind and is board certified in psychiatry, hospice and palliative medicine, and integrative medicine. He is the principal investigator for a psilocybin-enhanced group psychotherapy intervention for cancer patients with depression and a co-investigator on a study for ketamine-assisted psychotherapy for opioid use disorder. He has extensive experience with creating group therapy interventions for patients with serious illness and has successfully integrated ketamine-assisted psychotherapy services within an academic outpatient oncology clinic for cancer patients with depression. Dr. Thielking was director of psycho-oncology at the University of Utah Huntsman Cancer Institute for five years and previously an associate professor in the department of psychiatry at the University of Utah. He is a graduate of the California Institute of Integrative Studies' Certification of Psychedelic Therapy and Research program. Numinus is also pleased to announce that as a result of his growing responsibilities, Michael Tan has been promoted to President and Chief Operating Officer. In his new role, Mr. Tan will oversee all Company operations and will lead strategic directives to drive revenue growth through future footprint and product line expansions. Mr. Tan has been instrumental in Numinus' growth, and joined the Company in 2019. As a result of the increased medical and research expertise added to Numinus' expanded executive team, Dr. Evan Wood, Chief Medical Officer, will now be able to continue in his role in a reduced capacity, in order to enable him to maintain his important advocacy, clinical and teaching work. Dr. Wood remains committed to Numinus over the long term and will continue as the Company's Chief Medical Officer through the integration of Novamind, though with reduced office hours. Announcement • May 18
Numinus Wellness Inc. Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment Numinus Wellness Inc. announced that Health Canada has approved Numinus' application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression. This is Numinus' first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada's Special Access Program ("SAP"), which was amended January 5th, 2022 to include access to psychedelic compounds on a case-by-case basis. Psilocybin-assisted therapy has shown a great deal of promise in treating depression, as demonstrated in recent clinical trials and studies. The psychedelic-assisted therapy treatment will take place at one of Numinus' Montreal clinics, consisting of psilocybin-assisted therapy including several preparatory and integration therapy sessions, medical consults and one psilocybin-dosing session. All practitioners involved in the treatment have been trained through Numinus' proprietary psilocybin-assisted therapy protocol and Numinus will partner with Psygen Labs, an approved Health Canada supplier, to provide the synthetic psilocybin to be taken orally during the dosing session. Announcement • May 02
Numinus Announces the Music as Medicine Event Series Numinus Wellness Inc. announced that it is launching Music As Medicine by Numinus, a series of ceremonial concerts exploring the role music plays in psychedelic-assisted therapy and mental health. Music As Medicine by Numinus will feature a rotating roster of meditative and ambient musicians, including Jon Hopkins, East Forest and Superposition, multimedia art, and immersive guided meditations. Numinus is also showcasing its Music As Medicine by Numinus concept at DoubleBlind's Mycelia Festival in Ojai, California, as well as other cities, which will be announced soon. Board Change • Apr 27
High number of new and inexperienced directors There are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 1 experienced director. 1 highly experienced director. Independent Director Allen Morishita is the most experienced director on the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 16
Second quarter 2022 earnings released: CA$0.038 loss per share (vs CA$0.028 loss in 2Q 2021) Second quarter 2022 results: CA$0.038 loss per share (down from CA$0.028 loss in 2Q 2021). Net loss: CA$7.84m (loss widened 85% from 2Q 2021). Over the next year, revenue is forecast to grow 593%, compared to a 177% growth forecast for the industry in Canada. Announcement • Apr 02
Numinus Wellness Inc. to Report Q2, 2022 Results on Apr 14, 2022 Numinus Wellness Inc. announced that they will report Q2, 2022 results After-Market on Apr 14, 2022 Announcement • Mar 31
Numinus Wellness Inc. Completes First MDMA Administration in PTSD Trial Sponsored by MAPS Numinus Wellness Inc. announced that it has advanced to the next implementation phase in the clinical trial "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)" sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by MAPS Public Benefit Corporation (MAPS PBC), by enrolling and dosing the first clinical trial volunteer in Canada. Numinus hosts the Canadian sites for MAPPUSX, through two purpose-designed clinics located in Montreal and Vancouver. This week, the Montreal site began drug administration, led by trial co-therapists Dr. Joe Flanders, VP Psychology, Numinus, and Dr. Emma Hapke, Staff Psychiatrist, University Health Network and Principal Investigator for the MAPS-sponsored trial. The treatment follows MAPS' protocol of three sessions of MDMA administration and therapy, each to be followed by three integration sessions. The full program is expected to complete in mid-summer 2022. MAPPUSX is an extension of MAPS' Phase 3 studies to investigate the safety and efficacy of MDMA-assisted therapy for treating severe PTSD. The MAPPUSX trial is open to those participants from the Phase 3 studies who received the placebo drug and therapy and those who could not receive treatment due to COVID restrictions. The resulting safety data will be provided to regulatory bodies in the sponsor's New Drug Application. Announcement • Feb 02
Numinus Wellness Inc. Appoints New Bioscience Advisors to Advance IP Development Numinus Wellness Inc. announced the appointment of three key advisors to its new Bioscience Advisory Board. The following advisors have been appointed: Mr. Pechenik is a registered patent attorney and the founder of Calyx Law. Mr. Pechenik started Calyx Law to help cannabis and psychedelics ventures design and implement their IP strategies. Mr. Pechenik also contributes to Psilocybin Alpha as editor-at- large, writing about psychedelics IP and contributing to psychedelics patent, legalization, and decriminalization trackers, and is a member of Chacruna's Council for the Protection of Sacred Plants. Dr. Spagnuolo is a past member of the Natural Health Products Research Society of Canada and has received funding from the Canadian Institutes of Health Research (CIHR) and the Natural Sciences and Engineering Research Council of Canada (NSERC). Dr. Spagnuolo's research focuses on understanding the therapeutic potential of nutraceuticals (i.e. foods that provide medical or health benefits) and has included investigation of anti-cancer effects in certain compounds. He is experienced in developing novel, multidisciplinary techniques that combine drug discovery platforms traditionally used in the pharmaceutical industry with new areas of study. Dr. Cory Harris involves collaboration with Inuit and First Nations communities, and projects have included investigating the ethical and evidence-based use of alternative medicines and the health benefits and risks of wild plant foods. Dr. Harris also heads a graduate research community that undertakes special interest projects, operating out of UOttawa and supported by NSERC, Mitacs and the Province of Ontario. The new Bioscience Advisory Board will contribute strategically to advancing Numinus' IP strategy, including product development and clinical trial activities out of the Company's Health Canada-licensed research facility, Numinus Bioscience. It joins Numinus' existing General and Clinical advisory boards, comprised of leading industry and subject-matter experts who have been selected to support corporate and therapeutic protocol development. Among them are Drs. Gabor Maté, Dennis McKenna and Zachary Walsh. Reported Earnings • Jan 22
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint First quarter 2022 results: CA$0.026 loss per share (down from CA$0.017 loss in 1Q 2021). Net loss: CA$5.35m (loss widened 178% from 1Q 2021). Revenue missed analyst estimates by 1.3%. Over the next year, revenue is forecast to grow 472%, compared to a 87% growth forecast for the industry in Canada. Announcement • Jan 16
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product Numinus Wellness Inc. announced that it has formally submitted the clinical trial application ("CTA") to Health Canada for its Phase 1 study, HOPE, on a naturally derived Psilocybe extract formulation, NBIO-01. This milestone further progresses and solidifies Numinus' long-standing work on developing safe and effective psychedelic products out of its Health Canada-licensed research facility, Numinus Bioscience. NBIO-01 is Numinus Bioscience's first proprietary formulation developed from extracts generated using patent-pending technology, for which a patent was earlier submitted to the US Patent and Trade Office and announced on June 24, 2021. The formulation has been developed to stably deliver psilocybin and other synergistic compounds and will be studied for safety and bioavailability. As Numinus' first fully autonomous clinical trial, HOPE is a two-phase study that will take place at a Numinus clinic in Vancouver. Upon approval, Numinus will begin testing the extract for bioavailability and tolerability on 20 healthy volunteers, followed by testing against a psilocybin comparator on a further 28 healthy volunteers. Announcement • Dec 16
Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index Numinus Wellness Inc.(TSXV:NUMI) dropped from S&P/TSX Venture Composite Index Reported Earnings • Dec 11
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: CA$0.11 loss per share (up from CA$0.15 loss in FY 2020). Net loss: CA$18.8m (loss widened 96% from FY 2020). Revenue missed analyst estimates by 24%. Over the next year, revenue is forecast to grow 528%, compared to a 136% growth forecast for the pharmaceuticals industry in Canada. Announcement • Sep 24
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto. Numinus Wellness Inc. (TSXV:NUMI) agreed to acquire the Neurology Centre of Toronto for CAD 1 million on July 2, 2021. Numinus will pay CAD 0.3 million in cash and CAD 0.2 million in Numinus shares upon closing and future performance-based payments totaling up to CAD 0.5 million in Numinus shares to complete the transaction. Neurology Centre of Toronto reported gross revenue of CAD 1 million for December 31, 2020. Evan Lewis, recognized for advancing the use of medical cannabis to treat complex neurologic disorders, will join Numinus as Vice President, Psychedelic Neurology Services upon completion of the acquisition. All of NCT's staff - including medical doctors, nurses, physician assistants, occupational therapists, psychotherapists, physiotherapists, nutritionists and administrative staff - are expected to remain with Numinus post transaction closing. The transaction is subject to a number of conditions, including the approval of the TSX Venture Exchange. As of the date hereof, Numinus and NCT management have completed their due diligence. The Numinus Wellness Inc. anticipates that the acquisition of NCT will be completed by the end of August 2021.
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Neurology Centre of Toronto on September 23, 2021. NCT will operate as the Neurology Centre of Toronto by Numinus and continue under Evan Lewis' leadership. Reported Earnings • Jul 31
Third quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.035 loss in 3Q 2020) Third quarter 2021 results: Net loss: CA$4.82m (loss widened 46% from 3Q 2020). Announcement • Jul 14
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Numinus Wellness Inc. announced that Health Canada has cleared the MAPS-sponsored single-arm, open-label safety and feasibility study evaluating MDMA-assisted therapy for post-traumatic stress disorder. This study is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of MDMA-assisted therapy training programs, treatment protocols and research. This study has advanced through the pre-implementation stage at Numinus' Vancouver clinic and has now received the required federal regulatory approval. Study preparations are now transitioning into the final stages of training staff, importing medication and obtaining ethical approval to allow the recruitment of participants according to COVID-19 public health protocols. During the study, research, medical and therapist staff at Numinus will collect data on the safety and effectiveness of MDMA-assisted therapy to inform Health Canada and support making MDMA-assisted therapy available to individuals living with PTSD in Canada. Through the collaboration and study activities, Numinus seeks to create access for patients with no other treatment options and establish the physical, human resource and other infrastructure required to scale up access to MDMA-assisted therapy if federal approvals are ultimately in place. Announcement • May 11
Numinus Wellness Inc. Congratulates Multidisciplinary Association for Psychedelic Studies on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD Numinus Wellness Inc. ("Numinus" or the "Company") congratulated the Multidisciplinary Association for Psychedelic Studies (MAPS) and the MAPP1 trial study team for their announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD). The trial involved 90 participants with chronic PTSD. It demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with 67% no longer qualifying for PTSD diagnosis in comparison to 32% of participants randomized to placebo. Study participants had PTSD diagnoses from a range of causes, including combat-related events, accidents, abuse, sexual harm and developmental trauma. The results, published in the peer-reviewed medical journal Nature Medicine, presented no serious safety concerns, and confirmed earlier findings from MAPS' six completed Phase 2 clinical trials that demonstrated clear safety and efficacy of MDMA-assisted therapy. Phase 3 is the final phase of research required by regulators, such as Health Canada and the U.S. Food and Drug Administration (FDA), before deciding whether or not to approve MDMA as a legal prescription treatment for PTSD. Numinus and MAPS Public Benefit Corporation (PBC), a wholly-owned benefit subsidiary of MAPS, announced in December 2020 their collaboration on a compassionate access trial to deliver MDMA-assisted psychotherapy for PTSD for individuals with treatment-resistant PTSD who are unable to access MDMA-assisted therapy through a Phase 3 trial. Reported Earnings • May 03
Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.016 loss in 2Q 2020) Second quarter 2021 results: Net loss: CA$4.24m (loss widened 435% from 2Q 2020). Recent Insider Transactions Derivative • Apr 09
Independent Director exercised options to buy CA$158k worth of stock. On the 1st of April, Allen Morishita exercised options to buy 150k shares at a strike price of around CA$0.38, costing a total of CA$57k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since June 2020, Allen's direct individual holding has decreased from 1.17m shares to 1.06m. Company insiders have collectively sold CA$215k more than they bought, via options and on-market transactions in the last 12 months. Announcement • Mar 21
Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 35 million. Numinus Wellness Inc. has completed a Composite Units Offering in the amount of CAD 35 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 28,000,000
Price\Range: CAD 1.25
Discount Per Security: CAD 0.075 Announcement • Mar 06
Numinus Wellness Inc. Receives New Amendments Under Canada's Controlled Drugs and Substances Act Enhance the Company's Ability to Lead Psychedelics Research and Support the Global Psychedelics Sector Numinus Wellness Inc. has received new amendments under Canada's Controlled Drugs and Substances Act that enhance the company's ability to lead psychedelics research and support the global psychedelics sector. Numinus Bioscience, which operates a research lab in British Columbia, Canada, recently received amendments to its federal licence to allow the possession, production, assembly, sale, export, and delivery for a wide variety of psychedelics including - for the first time - Ketamine and Lysergic acid diethylamide (LSD). The amendment also supports Numinus Bioscience's role in these activities related to Mescaline, N, N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin. Among other valued-added services, the amendments enable Numinus Bioscience to pursue formulation and stability studies to assemble finished products for all approved psychedelics. Previously, Numinus Bioscience conducted R&D and analytical testing on Psilocybe mushrooms. New amendments allow Numinus Bioscience to conduct all activities related to possession, production, sale, export, delivery and assembly for Psilocybe mushroom fruiting bodies, both whole ground and extracted, to stakeholders that possess a Section 56 exemption. In addition, the new amendments allow Numinus Bioscience to increase the amount of Psilocin and Psilocybin produced at the lab from 505 grams to 1000 grams annually, consisting of 750 grams of Psilocybin and 250 grams of Psilocin. Health Canada has also acknowledged that the company can continue to supply verified and validated Psilocybe mushroom spores and tissue culture that do not contain controlled substances to other licensed dealers and can be listed as a supplier. In coming quarters, Numinus Bioscience will prepare to offer the expanded suite of psychedelic products and services allowed by recent amendments. Announcement • Mar 04
Numinus Wellness Inc. Announces Appointment of Several Key Members Numinus announced the appointment of several key members to the study, including Dr. Lindsay Mackay, MD, CCFP, a clinician-scientist and addictions specialist who has been selected as Principal Investigator. Dr. Mackay is a graduate of the British Columbia Centre on Substance Use, NIDA-funded International Collaborative Addictions Medicine Research Fellowship, and has extensive experience in the exploration of psychedelics and novel therapies as treatments for mental health and addictions. Elena Argento, PhD, MPH, has been appointed Co-Principal Investigator. Argento works collaboratively with the BC Centre on Substance Use to conduct and lead innovative research and interventions in response to the overdose crisis and is a Postdoctoral Researcher at the University of British Columbia. While psilocybin remains a restricted substance in Canada, the evolving regulatory landscape has shown the potential to enable greater accessibility to psilocybin-assisted psychotherapy, particularly in light of Health Canada's recent announcement of its intention to revise the Special Access Programme (SAP). The PRIME trial is expected to contribute to the growing interest in expanding access to psilocybin-assisted treatments. Announcement • Feb 19
Numinus Wellness Inc Announces Milestones in Compassionate Access Trial for Mdma-Assisted Therapy in Collaboration with Maps Public Benefit Corporation Numinus Wellness Inc. shared that the single-arm, open-label, compassionate access1 trial for MDMA-assisted therapy has made significant progress towards treating patients with posttraumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research, and MDMA-assisted therapy training programs. This first-of-its-kind trial in Canada has advanced and successfully transitioned into the pre-implementation stage at Numinus' Vancouver clinic. This follows the successful completion of several milestones, starting with the recruitment of therapists, physicians, and staff in preparation for participant enrolment and the ultimate analysis of therapy outcomes. The highly qualified cohort of medical staff will be responsible for collecting safety data for Health Canada to further implement key research that supports individuals living with PTSD who have not benefited from existing treatment options. In November 2020, eight Numinus therapists graduated from Part B of the MAPS MDMA therapist training program. Through their roles within the trial, they will complete the supervision requirement for certification as fully qualified MDMA therapists. A draft MDMA-assisted therapy protocol for PTSD has been adapted for the trial, including clear guidance surrounding necessary screening processes, patient health histories, and indications and potential contraindications before accepting participants. Initial regulatory meetings with Health Canada to define the trial's implementation science strategy have been completed, and the next steps will include obtaining ethical and Health Canada approvals to allow the recruitment of participants according to COVID-19 public health protocols. Numinus is also pleased to announce that its Medical and Therapeutic Services Director, Dr. Devon Christie, will serve as both the trial's Principal Investigator and as a therapist. Dr. Christie is a family physician with a focus in multidisciplinary pain management, is a certified Relational Somatic Therapist, and is already MAPS-trained in the delivery of the MAPS MDMA-assisted therapy for PTSD. Recent Insider Transactions • Feb 12
Independent Director recently sold CA$54k worth of stock On the 4th of February, Edwin Garner sold around 38k shares on-market at roughly CA$1.44 per share. In the last 3 months, there was an even bigger sale from another insider worth CA$118k. Insiders have been net sellers, collectively disposing of CA$150k more than they bought in the last 12 months. Recent Insider Transactions • Feb 10
Independent Director recently sold CA$54k worth of stock On the 4th of February, Edwin Garner sold around 38k shares on-market at roughly CA$1.44 per share. In the last 3 months, there was an even bigger sale from another insider worth CA$118k. Insiders have been net sellers, collectively disposing of CA$150k more than they bought in the last 12 months. Announcement • Feb 09
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Mindspace Psychology Services Inc. Numinus Wellness Inc. (TSXV:NUMI) entered into an agreement to acquire Mindspace Psychology Services Inc on December 15, 2020. The agreement of the transaction is CAD 0.5 million in cash upon closing of the transaction, a time-based payout of 441,176 common shares of Numinus issued over the course of 24 months, CAD 0.1 million in Numinus Shares, per year on each of the first three (3) anniversaries of the Closing Date, a multi-year performance payout of CAD 0.8 million in Numinus shares, issued at Market Price. The closing of the Transaction is subject to a number of conditions, including the approval of the TSX Venture exchange, and is expected to be completed by December 31, 2020.
Numinus Wellness Inc. (TSXV:NUMI) completed the acquisition of Mindspace Psychology Services Inc on February 8, 2021. 
